Table 2.

Patient characteristics stratified by creatinine slope

	Creatinine stable/decreased (n = 104)	Creatinine increased (n = 146)	P‐valuea
Clinical features
Age years	66 (57‐74)	68 (60‐77)	.18
Men	73 (70)	111 (76)	.30
Ischemic etiology	45 (43)	71 (49)	.40
BMI kg/m2	26.6 (24.1‐30.2)	26.8 (24.4‐30.2)	.83
Heart rate b.p.m.	68 (59‐77)	65 (60‐72)	.33
SBP mmHg	121 (110‐136)	120 (106‐132)	.26
DBP mmHg	75 (65‐80)	70 (60‐80)	.08
Congestion*	67 (64)	90 (62)	.65
NYHA III/IV	29 (28)	33 (23)	.34
CRT	35 (34)	43 (30)	.48
Echocardiographic featuresb
LVEF	31 (23‐40)	29 (23‐36)	.20
DiasLVD	64 (56‐71)	64 (59‐72)	.47
SysLVD	47 (41‐58)	52 (45‐60)	.043*
E/A ratio	0.8 (0.6‐1.3)	0.9 (0.6‐1.3)	.20
E/E′ ratio	9.6 (5.8‐13.3)	11.8 (7.9‐19.0)	.010*
Medical history
Prior MI	32 (31)	63 (43)	.047*
Atrial fibrillation	35 (34)	62 (43)	.16
Diabetes	27 (26)	50 (34)	.16
Hypertension	41 (39)	72 (49)	.12
COPD	9 (9)	22 (15)	.13
Medication prevalence (%)/average total daily dose (mg)
Beta‐blocker	89%/48 mg	91%/41 mg	.32
ACE‐I/ARBs	96%/23 mg	93%/25 mg	.21
Loop diuretics	89%/63 mg	93%/98 mg	.003*
MRAs	71%/25 mg	69%/21 mg	.022*
Cardiac biomarkers
NT‐proBNP ng/L	894 (279‐2158)	1369 (514‐2871)	.042*
cTnT ng/L	14.3 (8.3‐29.4)	20.1 (10.7‐38.1)	.018*
Renal glomerular indices (plasma)
Creatinine mg/dL	1.32 (1.08‐1.67)	1.10 (0.92‐1.38)	<.001*
eGFRmL/min/1.73 m 2	51 (37‐71)	65 (48‐82)	<.001*
eGFR<60	66 (64)	64 (44)	.002*
Renal tubular markers (urine)
NAG, U/gCr	5.5 (3.4‐8.5)	6.5 (3.9‐9.3)	.06
KIM‐1, ng/gCr	467 (244‐828)	505 (247‐995)	.21

Note: For description, please see Table 2; P‐values signify a trend across groups and the asterisk indicates P < .05.

^a p‐value for the difference in the average total daily dose.

^bBecause of logistic reasons, baseline LVEF, DiasLVD, and SysLVD were available in 74%, E/A ratio in 62%, and E/E′ ratio in 69% of all HFrEF patients.